事業内容
あなたはここにいる：ホーム > 事業内容
Medicilon offers comprehensive and FDA/CFDA GLP-compliant bioanalytical services to support preclinical and clinical development of small molecule drugs.
Medicilon's Toxicology has professional teams with rich experience in toxicology studies. Our study platform is certified as one of the Shanghai Public Service Research Platforms. Our Toxicology Research is all compliant with GLP or NON-GLP standards.
Medicilon's Safety pharmacology has professional teams with rich experience in toxicology studies. Our study platform is certified as one of the Shanghai Public Service Research Platforms. Our Toxicology Research is all compliant with GLP or NON-GLP standards.
Safety assessment for inhalation toxicology requires experience and specialized capabilities to successfully test the effects of inhaled compounds. Medicilon’s preclinical research department the complete inhalation toxicity assessment service system focusing on evaluating safety of new inhaled drugs for clients whenever needed.
Medicilon’s preclinical ophthalmic research platform is one experienced team integrating advanced drug delivery technology and analysis methodology. Equipped with state of the art devices, we can provide high-quality and efficient experimental research services, professional registration and application support and project management services for customers with ophthalmic drug development needs.
メディシロン社皮膚局所製剤開発プラットフォームは、軟膏剤、クリーム剤、ゲル化剤等の半固形製剤、及び洗浄剤、ローション等の液剤を含む様々な皮膚局所製剤の開発プロセスを受託し、国内外の規制やガイドラインの要件と完全に組み合わせ、長年の開発研究経験により、製薬会社や科学研究機関のためのいくつかの外部製剤研究プロジェクトの研究開発と申請を行った。
The solid screening platform of Medicilon process department strictly complies with the registration regulations and regulatory requirements of China NMPA, FDA and other regulatory authorities, studies and controls the solid morphology of drug molecules in API and preparations, and can formulate the optimal screening strategy according to the material characteristics, including but not limited to crystallization method, solvent selection and ion selection.
メディシロン社製造部門の原薬形態選定プラットフォームでは、中国NMPA、米国FDA等の監督管理部門の登録法規及び監督管理要求を遵守している。原薬及び製剤中薬物分子の原薬形態研究、管理では、結晶化法、溶媒選択、イオン選択のみならず、物質特性に基づいて厳密な原薬形態の選定を行っている。
